相关实验视频

Updated: Jun 27, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

探索新型因达衍生物作为ASK1抑制剂:设计,合成,生物评估和对接研究

Mengni He¹, Jie Wang¹, Wenhua Deng²

¹College of Pharmacy, Jiangxi University of Chinese Medicine, Nanchang 330004, PR China.

Bioorganic chemistry

|April 27, 2024

概括

一种基于因达的新型化合物33c有效抑制了亡信号调节激酶1 (ASK1). 这种ASK1抑制剂在降低肝脂和调节关键信号通路方面表现有前途,为非酒精性脂肪肝炎 (NASH) 提供了潜在的新疗法.

科学领域:

药用化学医学化学
分子生物学分子生物学
肝病学肝病学是一种肝病学.

背景情况:

亡信号调节激酶1 (ASK1) 是线粒激活蛋白激酶 (MAPK) 途径的关键调节者,影响细胞存活,应激反应和亡.
抑制ASK1激酶是一种有前途的治疗策略,用于非酒精性脂肪肝炎 (NASH).

研究的目的:

设计和合成针对ASK1激酶活性的新型因达基化合物.
在NASH的临床前模型中评估这些化合物的治疗潜力,特别是33c化合物.

主要方法:

进行了系统结构-活性关系 (SAR) 研究,以确定强大的ASK1抑制剂.
试验室试验评估了ASK1激酶抑制和对LO2细胞脂质代谢的影响.
在TNF-α治疗的HGC-27细胞中进行的机理学研究研究了该化合物对ASK1-p38/JNK信号通路和亡蛋白的影响.

主要成果:

一种新型的因达衍生物,化合物33c,显示出显著的ASK1抑制活性.
化合物33c减少了脂质滴积累,并降低了NASH模型细胞中的LDL,CHO和TG水平.
机理学研究证实了化合物33c抑制ASK1-p38/JNK通路和调节亡蛋白表达的能力.

结论:

化合物33c表现出强大的ASK1抑制,并证明在减少与NASH相关的细胞病理方面具有有效性.
这些发现突出了33c化合物作为进一步开发NASH治疗剂的有希望的候选物.

关键词:

ASK1 抑制剂的使用.设计设计设计设计设计设计.伊达的衍生品伊达的衍生品纳什·纳什 (Nash Nash) 是一个名为纳什的城市.综合合成综合合成

更多相关视频

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

相关概念视频

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...